GoodRx (GDRX)
(Delayed Data from NSDQ)
$7.81 USD
-0.01 (-0.13%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $7.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
GoodRx Holdings, Inc. (GDRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.50 | $16.00 | $5.00 | 21.48% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for GoodRx Holdings, Inc. comes to $9.50. The forecasts range from a low of $5.00 to a high of $16.00. The average price target represents an increase of 21.48% from the last closing price of $7.82.
Analyst Price Targets (18)
Broker Rating
GoodRx Holdings, Inc. currently has an average brokerage recommendation (ABR) of 1.94 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on 19 recommendations.
Of the 18 recommendations deriving the current ABR, nine are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 50% and 11.11% of all recommendations. A month ago, Strong Buy made up 47.37%, while Buy represented 10.53%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/GDRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 2 | 2 | 2 | 0 | 0 |
Hold | 6 | 6 | 7 | 9 | 9 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.94 | 1.94 | 2.00 | 2.11 | 2.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/23/2024 | Not Identified | Not Identified | Hold | Moderate Buy |
5/16/2024 | Raymond James | John W Ransom | Hold | Moderate Buy |
4/10/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Charles Rhyee | Strong Buy | Strong Buy |
3/25/2024 | Wells Fargo Securities | Stan Berenshteyn | Hold | Strong Buy |
3/5/2024 | Robert W. Baird & Co. | Vikram Kesavabhotla | Hold | Hold |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | UBS | Kevin Caliendo | Not Available | Hold |
3/1/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
3/1/2024 | Goldman Sachs | Eric J Sheridan | Hold | Hold |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Strong Buy |
9/18/2023 | Guggenheim Securities | Jack D Wallace | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.94 |
ABR (Last week) | 1.94 |
# of Recs in ABR | 18 |
Average Target Price | $9.50 |
LT Growth Rate | 12.60% |
Industry | Medical Services |
Industry Rank by ABR | 88 of 252 |
Current Quarter EPS Est: | 0.09 |